Investors in Zynerba Pharmaceuticals,
Inc. ZYNE need to pay close attention to the stock based
on moves in the options market lately. That is because the Apr 18,
2019 $7.50 Put had some of the highest implied volatility of all
equity options today.
What is Implied Volatility?
Implied volatility shows how much movement the market is expecting
in the future. Options with high levels of implied volatility
suggest that investors in the underlying stocks are expecting a big
move in one direction or the other. It could also mean there is an
event coming up soon that may cause a big rally or a huge sell off.
However, implied volatility is only one piece of the puzzle when
putting together an options trading strategy.
What do the Analysts Think?
Clearly, options traders are pricing in a big move for Zynerba
Pharmaceuticals shares, but what is the fundamental picture for the
company? Currently, Zynerba Pharmaceuticals is a Zacks Rank #2
(Buy) in the Medical â Genetic Drugs industry that ranks in the Top
42% of our Zacks Industry Rank. Over the last 60 days, one analyst
has increased the earnings estimates for the current quarter, while
none have revised their estimates downward. The net effect has
taken our Zacks Consensus Estimate for the current quarter from a
loss of 77 cents per share to a loss of 46 cents in that
period.
Given the way analysts feel about Zynerba Pharmaceuticals right
now, this huge implied volatility could mean thereâs a trade
developing. Often times, options traders look for options with high
levels of implied volatility to sell premium. This is a strategy
many seasoned traders use because it captures decay. At expiration,
the hope for these traders is that the underlying stock does not
move as much as originally expected.
Looking to Trade Options?
Each week, our very own Dave Bartosiak gives his top options
trades. Check out his recent live analysis and options trade for
the NFLX earnings report completely free. See it here: Bartosiak:
Trading Netflix's (NFLX) Earnings with Options or check out the
embedded video below for more details:
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free
report
Zynerba Pharmaceuticals,
Inc. (ZYNE) : Free Stock Analysis Report
To read this article on
Zacks.com click here.
Zacks Investment Research